Compare MCS & CSTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MCS | CSTL |
|---|---|---|
| Founded | 1935 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Movies/Entertainment | Medical Specialities |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 676.9M | 722.8M |
| IPO Year | 1994 | 2019 |
| Metric | MCS | CSTL |
|---|---|---|
| Price | $30.69 | $30.39 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 6 |
| Target Price | $23.33 | ★ $45.50 |
| AVG Volume (30 Days) | 225.2K | ★ 372.2K |
| Earning Date | 04-30-2026 | 05-06-2026 |
| Dividend Yield | ★ 1.69% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.77 | N/A |
| Revenue | ★ $758,458,000.00 | $344,229,000.00 |
| Revenue This Year | $12.05 | $2.42 |
| Revenue Next Year | $3.15 | $12.69 |
| P/E Ratio | $37.79 | ★ N/A |
| Revenue Growth | 3.11 | ★ 3.66 |
| 52 Week Low | $12.85 | $17.72 |
| 52 Week High | $29.75 | $44.28 |
| Indicator | MCS | CSTL |
|---|---|---|
| Relative Strength Index (RSI) | 84.63 | 77.31 |
| Support Level | $14.96 | $22.67 |
| Resistance Level | N/A | $34.97 |
| Average True Range (ATR) | 1.08 | 1.48 |
| MACD | 0.72 | 0.45 |
| Stochastic Oscillator | 84.77 | 93.53 |
Marcus Corp is engaged in two business segments, which are movie theatres and Hotels and Resorts. The movie theatres segment operates multiscreen motion picture theatres in Wisconsin, Illinois, Iowa, Minnesota, Missouri, Nebraska, North Dakota, Ohio and others, a family entertainment center in Wisconsin and a retail center in Missouri; Hotels and Resorts segment owns and operates full-service hotels and resorts in Wisconsin, Illinois, and Nebraska and manages full-service hotels, resorts and other properties in Wisconsin, Minnesota, Texas, Nevada, California, and North Carolina. It generates maximum revenue from the Theatres segment.
Castle Biosciences Inc is a molecular diagnostics company. The group provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), and uveal melanoma. The product portfolio of the company includes DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a test to predict future development of progression of high-grade dysplasia and/or esophageal cancer. The company derives revenues through the delivery of test reports for its molecular diagnostic tests.